NAUT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAUT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Nautilus Biotechnology has the Profitability Rank of 1. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1. Operating Margin %Nautilus Biotechnology's Operating Margin % for the quarter that ended in Mar. 2024 was %. As of today, Nautilus Biotechnology's Piotroski F-Score is 2.
For the Biotechnology subindustry, Nautilus Biotechnology's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Nautilus Biotechnology's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Nautilus Biotechnology's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Nautilus Biotechnology has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Nautilus Biotechnology's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:
Operating Margin % | = | Operating Income (Q: Mar. 2024 ) | / | Revenue (Q: Mar. 2024 ) |
= | -21.607 | / | 0 | |
= | % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Nautilus Biotechnology has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Thank you for viewing the detailed overview of Nautilus Biotechnology's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael Seth Altman | director | C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Subramanian Sankar | officer: Senior VP, Product Development | C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070 |
Gwen E Weld | officer: Chief People Officer | C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121 |
Anna Mowry | officer: CFO and Treasurer | C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070 |
Matthew B. Murphy | officer: General Counsel | C/O NAUTILUS BIOTECHNOLOGY, INC., 425 PONTIUS AVE N, STE 202, SEATTLE WA 98109 |
Sujal M Patel | director, 10 percent owner, officer: CEO, President, and Secretary | C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121 |
Mary E. Godwin | officer: Senior VP, Operations | 3101 WESTERN AVENUE, SEATTLE WA 98121 |
Karen Akinsanya | director | SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joseph Edelman | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Perceptive Advisors Llc | director | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Matthew L. Posard | director | 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Matthew S Mcilwain | director | 1000 SECOND AVENUE, SUITE 3700, SEATTLE WA 98104 |
Benjamin A Horowitz | 10 percent owner | 2865 SAND HILL ROAD #101, MENLO PARK CA 94025 |
Marc L Andreessen | 10 percent owner | C/O ARNOLD & PORTER LLP, 3 EMBARCADERO CENTER 7TH FLOOR, SAN FRANCISCO CA 94111 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 01-27-2022
By Marketwired • 07-11-2023
By Don Li2 Don Li2 • 11-02-2021
By GuruFocus Research GuruFocus Editor • 11-25-2021
By GuruFocus Research • 10-31-2023
By Marketwired • 10-11-2023
By GuruFocusNews GuruFocusNews • 04-07-2022
By Stock market mentor Stock market mentor • 01-26-2023
By GuruFocus Research GuruFocus Editor • 12-02-2021
By Ds*** Ds*** • 09-01-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.